Thanks to early multimodal screening, breast cancer in people carrying BRCA1 or BRCA2 mutations can be diagnosed at an early stage, with consequent favorable effects on their survival and quality of life, and also on costs for the health system [2]. This evidence concerns the gene BRCA2 and breast cancer.